Pyoderma gangrenosum - Gangrenosum Pioderma
Gangrenosum Pioderma (Pyoderma gangrenosum) ir reta, iekaisīga ādas slimība, kurā sāpīgas pustulas vai mezgliņi kļūst par čūlām, kas pakāpeniski aug. gangrenosum pioderma (pyoderma gangrenosum) nav infekciozs. Ārstēšana var ietvert kortikosteroīdus, ciklosporīnu vai dažādas monoklonālas antivielas. Lai gan tas var skart cilvēkus jebkurā vecumā, tas galvenokārt skar cilvēkus vecumā no 40 līdz 50 gadiem.
☆ 2022. gada Stiftung Warentest rezultātos no Vācijas patērētāju apmierinātība ar ModelDerm bija tikai nedaudz zemāka nekā ar maksas telemedicīnas konsultācijām.
Uz kājas cilvēkam ar čūlaino kolītu.
References
Pyoderma gangrenosum ir reta ādas slimība, kas izraisa sāpīgas čūlas ar sarkanām vai purpursarkanām malām. Tā ir klasificēta kā iekaisuma slimība un ir daļa no grupas, ko sauc par neitrofilajām dermatozēm. Pyoderma gangrenosum cēlonis ir sarežģīts, ietverot problēmas gan ar iedzimtu, gan adaptīvu imunitāti cilvēkiem, kuriem ir ģenētiska nosliece. Nesen pētnieki ir koncentrējušies uz matu folikulu kā potenciālu slimības sākumpunktu.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum ir reta ādas slimība, kas izraisa ārkārtīgi sāpīgas čūlas. Lai gan mēs pilnībā nesaprotam tās cēloni, mēs zinām, ka tas ir saistīts ar noteiktu imūno šūnu aktivitātes palielināšanos. Slimību joprojām nav viegli izārstēt. Mums ir dažādas zāles, kas nomāc imūnsistēmu vai modificē tās darbību. Līdztekus tiem mēs koncentrējamies arī uz brūču ārstēšanu un sāpju pārvaldību. Kortikosteroīdi un ciklosporīns bieži ir pirmā izvēle ārstēšanai, taču pēdējā laikā ir veikti vairāk pētījumu par bioloģisko terapiju, piemēram, TNF-α inhibitoru, lietošanu. Šiem bioloģiskajiem preparātiem arvien vairāk tiek dota priekšroka, īpaši pacientiem ar citiem iekaisuma stāvokļiem, un tos lieto agrāk slimības procesā.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
